US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Scantox continues its growth journey with the acquisition of Solural Pharma

Scantox A/S (“Scantox”) announces the acquisition of Solural Pharma (“Solural”) in Denmark. Scantox is the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo. Solural has strong expertise in all aspects of formulation development, GMP manufacturing and packaging to support phase 1 & 2 clinical trials. Solural develops formulations, from concept idea to clinical proof of concept. The company’s formulation technology platform provides innovative oral and topical products having unique benefits regarding

Scantox appoints Morten Fjordholt as Sr. Business Development Director

November 8th – Scantox Group, a leading provider of nonclinical services in Europe, has named Morten Fjordholt as Sr. Business Development Director with the overall responsibility of growing sales within toxicology and lab services and fostering positive relationships with current and prospective clients. Morten Fjordholt is an experienced Molecular Biologist and pharmaceutical Toxicologist with over two decades of experience in the life science and drug development industry. Morten has made significant contributions to our industry. Over the past eight years, he played a crucial role in

Scantox acquires Q&Q – strengthening its offering within bioanalytical services

Scantox A/S (“Scantox” or the “Company”), the leading Nordic GLP-compliant pre-clinical contract research organization (“CRO”), headquartered in Denmark and since 2021 owned by Impilo, is pleased to announce the acquisition of Q&Q Labs AB located in Gothenburg, Sweden (“Q&Q”).   Q&Q is a leading provider of tailor made bioanalytical services and brings a highly complementary service offering to Scantox’s stronghold in pharmacology and regulatory toxicology. Through the acquisition, Scantox will  boost its analytical capabilities, scientific expertise and capacity with the aim of

Scantox appoints Andy Brown as Group Chief Commercial Officer

July 7th – Scantox Group, a leading provider of nonclinical services in Europe, has named Andy Brown as Group Chief Commercial Officer with the overall responsibility of growing sales within toxicology, discovery and lab services and fostering positive relationships with current and prospective clients. Together with the executive management team and Impilo, Andy will be part of Scantox Group overall strategy of driving the organic and inorganic growth of Scantox. “We will continue to focus our efforts on doing the things that customers value most while enhancing our preclinical services

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media